Alk-Abello ASWBO:ALKB -0.12%66 EBITDA Margin % is 36.93% as of Mar. 2026, which is 149% above its 10-year median of 14.81. GuruFocus rates WBO:ALKB with a GF Score™ of 66/100 and a GF Value™ of €27.26 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 944 Biotechnology companies, Alk-Abello AS ranks better than 89.51% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Alk-Abello AS's EBITDA for the
three
months ended in Mar. 2026 was €87.5 Mil. Alk-Abello AS's Revenue for the
three
months ended in Mar. 2026 was €236.9 Mil. Therefore, Alk-Abello AS's EBITDA margin for the quarter that ended in Mar. 2026 was 36.93%.
Alk-Abello AS (WBO:ALKB) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Alk-Abello AS EBITDA Margin % Related Terms
Alk-Abello AS EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Alk-Abello AS's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:ALKB vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Alk-Abello AS's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alk-Abello AS EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alk-Abello AS's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Alk-Abello AS's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alk-Abello AS (WBO:ALKB) has a EBITDA Margin % of 36.93% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Alk-Abello AS and its competitors. This is 149% above median its historical median of 14.81. Over the past decade, Alk-Abello AS's EBITDA Margin % has ranged from 5.28 to 32.13. According to the industry distribution chart, Alk-Abello AS ranks #99 out of 944 companies in the Biotechnology industry, placing it in the top 10.5%.
Is Alk-Abello AS's EBITDA Margin % too high?
Alk-Abello AS's current EBITDA Margin % of 36.93% is 149% above median its 10-year median of 14.81. Over the past 10 years, this metric has ranged from a low of 5.28 to a high of 32.13. Based on the distribution chart, Alk-Abello AS ranks #99 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Alk-Abello AS has a GF Score™ of 66/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alk-Abello AS's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alk-Abello AS ranks #99 out of 944 companies for EBITDA Margin %. This places Alk-Abello AS in the top 11% of its industry — outperforming the majority of peers. Historically, Alk-Abello AS's own EBITDA Margin % has ranged from 5.28 to 32.13 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Alk-Abello AS and its competitors. Alk-Abello AS's current EBITDA Margin % is 36.93%, which is 149% above median its own 10-year median of 14.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alk-Abello AS stock overvalued right now?
Based on GuruFocus' analysis, Alk-Abello AS (WBO:ALKB) is currently considered Modestly Overvalued. The stock's GF Value™ is €27.26, compared to a current price of €34.22 — trading 25.5% above its estimated fair value. The current EBITDA Margin % is 36.93%, which is 149% above median its 10-year median of 14.81. Alk-Abello AS's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Alk-Abello AS (WBO:ALKB), the current EBITDA Margin % is 36.93% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alk-Abello AS (WBO:ALKB) Overvalued in 2026?
Based on GuruFocus' analysis, Alk-Abello AS stock appears to be overvalued.
The current stock price of €34.22 is trading 25.5% above its estimated GF Value™ of €27.26.
GuruFocus considers Alk-Abello AS to be Modestly Overvalued.
Key valuation signals for WBO:ALKB:
EBITDA Margin %: 36.93% (149% above median its 10-year median of 14.81)
GF Value™: €27.26 vs. price of €34.22 (25.5% above fair value)
No single metric tells the full story. See the WBO:ALKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
66GF Score
Get the complete analysis for WBO:ALKB
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:ALKB has been successfully added to your 
